Nuvation Bio (NUVB) RBC Capital Markets Global Healthcare Conference 2026 summary

Commercial performance and growth drivers

• IBTROZI achieved $18.5 million in Q1 revenues with about 200 new patient starts per quarter, outpacing competitors in new patient starts.

• First-line patient share among new starts has grown from 30% to over 50% in three quarters, driving durable revenue due to longer treatment duration (4+ years per patient).

• Revenue growth is expected from increased first-line share, greater physician familiarity, and changes in NCCN guidelines making ROS1 agents mandatory for ROS1 lung cancer.

• Enhanced testing rates, especially with RNA-based tests and new state mandates, are expected to expand the eligible patient pool from 3,000 to 4,000 annually in the U.S.

• IBTROZI’s strong efficacy (90% response rate, 50-month duration) and tolerability profile are key differentiators in a competitive market.

Market dynamics and competitive landscape

• National guidelines and state legislation are driving increased genetic testing, with Louisiana requiring NGS testing for lung cancer and other states considering similar laws.

• IBTROZI’s CNS activity is a major differentiator, with a 66% intracranial response rate, outperforming competitors in treating brain metastases.

• Efficacy and safety are viewed as intertwined, with IBTROZI offering the longest duration of response and lowest discontinuation rates among peers.

• The company is the only one conducting an adjuvant study in ROS1, enabled by the drug’s tolerability.

Safusidenib program and clinical development

• Safusidenib shows superior efficacy in low risk, low-grade glioma compared to the approved agent, with a 44% response rate and lower progression rates at one and two years.

• In high-grade glioma, safusidenib achieved a 17% response rate, including complete responses in challenging cases like GBM.

• Three clinical studies are underway: SIGMA (PFS endpoint, reads out 2029), a Grade 3 oligodendroglioma response rate study (reads out next year), and a post-VORANIGO progression study.

• Large prevalence pool for IDH1 glioma (tens of thousands of patients) supports a multibillion-dollar commercial opportunity, potentially exceeding IBTROZI.

• Safusidenib’s unique immune-related adverse events and delayed, durable responses suggest a novel mechanism of action.